for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Qiagen NV

QGEN.N

Latest Trade

32.26USD

Change

-0.11(-0.34%)

Volume

530,405

Today's Range

32.04

 - 

32.64

52 Week Range

25.06

 - 

41.52

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Qiagen Reports Qtrly Adjusted EPS Of $0.36

Oct 30 (Reuters) - Qiagen NV <QIA.DE>::QIAGEN REPORTS FULL RESULTS FOR THIRD QUARTER AND FIRST NINE MONTHS OF 2019.QTRLY NET LOSS PER SHARE OF $0.71.QTRLY ADJUSTED EPS OF $0.36.QTRLY NET SALES OF $382.7 MILLION, UP 1% ACTUAL AND UP 3% AT CONSTANT EXCHANGE RATES.UPDATES FULL-YEAR 2019 OUTLOOK FOR NET SALES GROWTH OF ABOUT 4% CER AND ADJUSTED. EPS OF ABOUT $1.43-$1.44 CER.Q3 EARNINGS PER SHARE VIEW $0.35, REVENUE VIEW $383.1 MILLION -- REFINITIV IBES DATA.FY2019 EARNINGS PER SHARE VIEW $1.38, REVENUE VIEW $1.53 BILLION -- REFINITIV IBES DATA.DISCONTINUING DEVELOPMENT OF NEW NGS INSTRUMENTS AND OTHER MEASURES RESULTED IN PRE-TAX CHARGE OF $276.8 MILLION IN OPERATING RESULTS FOR Q3 2019.

Qiagen Says Shifting Global Operations Organization To Regional Manufacturing Structure

Oct 7 (Reuters) - Qiagen NV <QIA.DE>::QIAGEN NV - SHIFTING ITS GLOBAL OPERATIONS ORGANIZATION TO A REGIONAL MANUFACTURING STRUCTURE.QIAGEN NV - PLANS TO TAKE A PRE-TAX RESTRUCTURING CHARGE OF ABOUT $260-$265 MILLION PREDOMINANTLY IN Q3.QIAGEN NV - EXPANDING SCOPE OF ACTIVITIES AT QIAGEN BUSINESS SERVICES CENTERS IN WROCLAW, POLAND, AND MANILA, PHILIPPINES.QIAGEN NV - ANY RELATED WORKFORCE REDUCTIONS WILL BE HANDLED IN COMPLIANCE WITH LOCAL LABOR LAWS.QIAGEN NV - PLANS TO TAKE A PRE-TAX RESTRUCTURING CHARGE OF ABOUT $1.14-$1.15 PER SHARE AFTER TAXES PREDOMINANTLY IN Q3.QIAGEN NV - $260-$265 MILLION PRE-TAX RESTRUCTURING CHARGE INCLUDES APPROXIMATELY $195-$200 MILLION OF NON-CASH ITEMS.QIAGEN - ABOUT $195-$200 MILLION OF NON-CASH ITEMS IN PRE-TAX RESTRUCTURING CHARGE PRIMARILY RELATED TO DECISION ON NGS INSTRUMENT DEVELOPMENT ACTIVITIES.

Qiagen Sees Q3 Prelim Total Net Sales Growth Of About 3%

Oct 7 (Reuters) - Qiagen NV <QIA.DE>::QIAGEN REPORTS PRELIMINARY Q3 2019 RESULTS AND ANNOUNCES MEASURES TO PRIORITIZE RESOURCE ALLOCATION.QIAGEN NV - ANTICIPATES Q3 ADJUSTED EPS WITHIN ITS OUTLOOK FOR APPROXIMATELY $0.35-0.36 CER.QIAGEN NV SEES Q3 2019 PRELIMINARY TOTAL NET SALES GROWTH OF ABOUT 3% AT CONSTANT EXCHANGE RATES COMPARED TO OUTLOOK FOR ABOUT 4-5% CER GROWTH.

Qiagen Says Peer Schatz To Step Down As CEO

Oct 7 (Reuters) - Qiagen NV <QIA.DE>::QIAGEN ANNOUNCES CEO LEADERSHIP TRANSITION.QIAGEN NV - PEER M. SCHATZ TO STEP DOWN AS CEO TO PURSUE NEW OPPORTUNITIES.QIAGEN NV - SCHATZ REMAINS AS SPECIAL ADVÍSOR TO FACILITATE A SMOOTH TRANSITION.QIAGEN NV - THIERRY BERNARD TO ACT AS INTERIM CEO, WORKING IN TANDEM WITH CFO ROLAND SACKERS.QIAGEN NV - SEARCH STARTED FOR PERMANENT CEO TO LEAD QIAGEN IN NEXT GROWTH PHASE.

Qiagen Announces Change In Global Sales Structure

Sept 10 (Reuters) - Qiagen NV <QIA.DE>::QIAGEN ANNOUNCES CHANGE IN GLOBAL SALES STRUCTURE.DECIDED TO INTEGRATE ITS GLOBAL SALES RESOURCES INTO ITS BUSINESS AREAS (LIFE SCIENCES, MOLECULAR DIAGNOSTICS AND BIOINFORMATICS).PLANS TO PROVIDE AN UPDATE DURING Q4 OF 2019.MANUEL O. MENDEZ, SENIOR VICE PRESIDENT, GLOBAL COMMERCIAL OPERATIONS AND A MEMBER OF EXECUTIVE COMMITTEE, HAS RESIGNED TO ACCEPT A NEW CAREER OPPORTUNITY, AND LEAVE COMPANY IN OCTOBER 2019.

Qiagen Affirms Q2 Results

July 31 (Reuters) - Qiagen::Results remain unchanged from those announced July 24.Qiagen delivers on Q2 2019 outlook.Net sales of $381.6 million.Diluted EPS of $0.19.

Qiagen Says Total Net Sales Rose 1% To $381.6 Mln In Q2 Of 2019

July 24 (Reuters) - Qiagen NV <QIA.DE>::QIAGEN REPORTS RESULTS FOR SECOND QUARTER OF 2019; UPDATES FULL-YEAR 2019 OUTLOOK DUE TO DECISION TO RESTRUCTURE CHINA NGS PARTNERSHIP.INTENDS TO RESTRUCTURE CURRENT FORMAT OF ITS NEXT-GENERATION SEQUENCING (NGS) PARTNERSHIP IN CHINA.TOTAL NET SALES ROSE 1% TO $381.6 MILLION IN Q2 OF 2019 FROM $377.2 MILLION IN Q2 OF 2018.SAYS NET INCOME WAS $44.7 MILLION IN Q2 OF 2019, OR $0.19 PER DILUTED SHARE COMPARED TO $36.8 MILLION, OR $0.16 PER SHARE.QTRLY ADJUSTED NET INCOME WAS $77.4 MILLION, OR $0.33 PER DILUTED SHARE.QTRLY OPERATING INCOME WAS $60.2 MILLION COMPARED TO $53.3 MILLION IN SAME QUARTER OF 2018.

Qiagen's Says Now Expects Full-Year 2019 Net Sales Growth Of About 5-6% CER

July 24 (Reuters) - Qiagen NV <QIA.DE>::DGAP-ADHOC: QIAGEN N.V. QIAGEN'S RESULTS FOR SECOND QUARTER 2019 IN LINE WITH OUTLOOK AT CER, REVISED FULL-YEAR 2019 OUTLOOK DUE TO INTENDED RESTRUCTURING OF CHINA NGS PARTNERSHIP.QIAGEN NV SAYS QIAGEN NOW EXPECTS FULL-YEAR 2019 NET SALES GROWTH OF APPROXIMATELY 5-6% CER (PREVIOUSLY ABOUT 7-8% CER).QIAGEN NV SAYS NOW EXPECTS FY 2019 ADJUSTED DILUTED EPS OF APPROXIMATELY $1.42-1.44 CER PER SHARE (PREVIOUSLY ABOUT $1.45-1.47 CER).QIAGEN- CO INTENDS TO RESTRUCTURE CURRENT FORMAT OF ITS NGS PARTNERSHIP IN CHINA DUE TO SLOWER-THAN-EXPECTED UPTAKE OF INVITRO DIAGNOSTIC CLINICAL SEQUENCING.QIAGEN NV SAYS FOR Q3 OF 2019, QIAGEN EXPECTS NET SALES TO GROW APPROXIMATELY 4-5% CER.QIAGEN NV SAYS FOR Q3 OF 2019 ADJUSTED DILUTED EPS IS EXPECTED TO BE ABOUT $0.35-0.36 CER PER SHARE.

Qiagen Expands Collaboration With Diasorin On Lyme Disease Research

June 5 (Reuters) - Qiagen <QIA.DE>::QIAGEN AND DIASORIN COLLABORATE ON NOVEL QUANTIFERON-BASED TEST WITH BREAKTHROUGH POTENTIAL FOR EARLIER DETECTION OF LYME DISEASE.COMPANIES PLAN MULTI-SITE CLINICAL VALIDATIONS DURING 2020 LYME DISEASE SEASON.REGULATORY SUBMISSIONS EXPECTED AT END OF SAME YEAR IN UNITED STATES AND EUROPE.

FDA Approves Novartis' Piqray, the First Pi3k Inhibitor For Breast Cancer

May 24 (Reuters) - U.S. Food and Drug Administration::FDA APPROVES FIRST PI3K INHIBITOR FOR BREAST CANCER.FDA APPROVES FIRST PI3K INHIBITOR FOR BREAST CANCER.FDA- ALSO APPROVED COMPANION DIAGNOSTIC TEST, THERASCREEN PIK3CA RGQ PCR KIT, TO DETECT PIK3CA MUTATION IN A TISSUE AND/OR A LIQUID BIOPSY.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up